Wegovy, Mounjaro or Rybelsus - injection or daily tablet

For most of the modern weight management story, GLP-1 medication has meant a once-weekly injection. That is changing. We now prescribe three first-line options at LoveMyLife: Wegovy (semaglutide injection), Mounjaro (tirzepatide injection) and Rybelsus (oral semaglutide). All three are licensed medicines in the UK and evidence-based. Wegovy and Mounjaro carry an MHRA weight-management licence; Rybelsus is MHRA-licensed for type 2 diabetes and is prescribed off-label for weight management, which is a normal and legal part of UK medical practice where the evidence supports it. The choice between the three is one we make with you in your first consultation.

This article walks through what the choice actually involves, so you arrive at the consultation with a clear sense of the trade-offs.

What the three options share

All three work by the same biological route. They are GLP-1 receptor agonists (Wegovy and Rybelsus contain semaglutide; Mounjaro contains tirzepatide, which adds a second hormone, GIP). They quiet food noise, slow gastric emptying, and shift the satiety signal so a normal portion feels like enough. The mechanism is the same whether the medication enters the bloodstream through your skin or through your gut wall.

What differs is the dose that reaches your system, the rhythm of taking it, and the practical demands on you week by week.

What is different in practice

Wegovy (semaglutide injection): one self-administered injection a week. Maintenance dose 2.4mg, with a higher 7.2mg dose newly available in the UK. Average weight loss of around 15 percent at 2.4mg and 20.7 percent at 7.2mg over a year. Strong cardiovascular outcome data in patients with existing heart disease.

Mounjaro (tirzepatide injection): one self-administered injection a week. Maintenance dose typically 10-15mg. Average weight loss of around 22.5 percent at the 15mg dose over 72 weeks, and stronger HbA1c effect for patients with type 2 diabetes or pre-diabetes.

Rybelsus (oral semaglutide): one tablet a day, taken on an empty stomach with no more than 120ml of plain water, at least 30 minutes before eating or drinking anything else. Maximum daily dose 14mg. Average weight loss of around 4-5 percent over a year, with newer trial data on higher 25mg and 50mg oral doses showing 13-15 percent (those higher-dose oral formulations are not yet UK-licensed for weight management).

The numbers tell you something important. At currently licensed doses, the injectables produce more weight loss than the tablet. That gap is not because semaglutide injection is a different drug from Rybelsus; it is the same drug. The gap is because only about 0.4-1 percent of each Rybelsus tablet survives stomach acid and crosses the gut wall into the bloodstream. The rest passes through.

What this means for the choice

Three patterns we see in consultation:

The patient who wants the maximum result and is comfortable with a weekly injection chooses Mounjaro or Wegovy. They want the medication to do as much of the work as possible. Both injectables are reasonable; we narrow between them based on your cardiovascular profile, HbA1c, history of side effects, and personal preference.

The patient who genuinely cannot face an injection, or has a strong needle aversion that working through is not the right call, chooses Rybelsus. The treatment is real, the weight loss is real, and the daily routine is manageable for many people. The trade-off is the lower ceiling and the strict fasting window every morning.

The patient who has already had a successful injectable course and wants a lower-effort maintenance phase chooses Rybelsus for that phase. This is an emerging pattern: inject for twelve to eighteen months to land at your goal weight, then switch to daily oral for the years that follow.

None of these patterns is automatically the right answer. What matters is that the option you choose fits how you want to live with the medication.

The Rybelsus routine, in plain terms

Rybelsus is the most demanding of the three on day-to-day routine. The medication has to be taken first thing, with a sip of plain water, before anything else passes your lips. That includes coffee, tea, fruit juice, breakfast, milk and oat milk in your tea, and your morning vitamins. You wait at least thirty minutes, ideally a bit longer, then carry on with your day.

For some people this is straightforward. They are already morning-routine people; they take their tablet on waking, get ready, and have breakfast forty minutes later. For others the daily fast on waking is the dealbreaker. It is honest to test how you actually wake up before choosing this option. If your hand reaches for the coffee jar before your brain switches on, Rybelsus will be hard.

What about oral Mounjaro and the new oral GLP-1s

There is a generation of oral GLP-1 medication coming through the pipeline. Eli Lilly has a tablet form of tirzepatide (oral Mounjaro) in late-stage trials. Eli Lilly also has orforglipron, a small-molecule oral GLP-1 agonist that does not require the strict fasting routine Rybelsus does, with early data suggesting weight loss closer to injectable levels. Neither is UK-licensed yet; both are expected in the next twelve to twenty-four months.

When they arrive we will assess them on their evidence and add them to the menu of options we offer. We do not recommend new medication just because it is new; we wait to see how it performs in real patients.

How we make the call with you

In your first consultation we work through your goals, your BMI and clinical picture, your tolerance for an injection, your morning routine, and what you want the next year of your life to look like. We tell you what we think, you tell us what fits, and we agree on the medication together. You are not locked in. If you start on Rybelsus and decide three months in that you would rather try an injection, we switch you at your next review with no additional assessment charge.

The honest summary

Wegovy, Mounjaro and Rybelsus are three working answers to the same problem. The injectables produce more weight loss on average. The tablet produces less but suits some lives better. The honest question is not which one is best; it is which one is best for you.

[Begin your consultation](/services/weight-management/prepare) with our weight management doctors.

Ready to start?

If this article has made you think medication might help, the next step is a short consultation with one of our weight-management doctors.

Begin your assessment at this link. Online in 30 minutes, or in person at Westfield London.